Synbiotic mulberry ameliorates kidney injury in dextran sodium sulfate-induced colitis rats

Abstract

Objective: To investigate the effect of synbiotic mulberry on kidney injury in a dextran sodium sulfate (DSS)-induced colitis model.

Methods: Male Wistar rats were given drinking water containing 4% DSS for 7 days. Subsequently, the rats were treated by oral gavage with synbiotic mulberry at 250, 500, and 1000 mg/kg, sulfasalazine at 100 mg/kg, or synbiotic at 1000 mg/kg for an additional 7 days while receiving 0.4% DSS in drinking water. The severity of colitis was evaluated based on the disease activity index score. On day 14, plasma was collected, and the kidneys were harvested to evaluate kidney injury parameters and histological changes. In addition, the expression of genes associated with kidney injury was determined by quantitative RT-PCR.

Results: Treatment with all doses of synbiotic mulberry significantly lowered the disease activity index score, accompanied by reductions in kidney histopathological changes, malondialdehyde concentration, and plasma cystatin C levels. Kidney fibrosis was also ameliorated by 500 and 1000 mg/kg of synbiotic mulberry. Treatment with 250 and 500 mg/kg of synbiotic mulberry downregulated IL-18 mRNA expression, while KIM-1 mRNA expression was reduced and plasma lipopolysaccharide-binding protein level was restored by 1000 mg/kg of synbiotic mulberry.

Conclusions: Synbiotic mulberry ameliorates kidney injury in rats with DSS-induced colitis. It may be further explored as a treatment of kidney injury under colitis conditions.

Keywords

Colitis / Mulberry / Synbiotic / Dextran sodium sulfate / Kidney injury

Conflict of interest statement

The authors declare that they have no conflict of interest.

Funding

This study was supported by the Mae Fah Luang University Research Development Grant 2023, Mae Fah Luang University, Chiang Rai Thailand (Grant no. 661B07007 to KW) and the Technology and Innovation-Based Enterprise Development Fund: Fund (Grant no. YP043/2565 to AO and PW).

Data availability statement

The data supporting the findings of this study are available from the corresponding author upon request.

Authors’ contributions

KW, AO, PW, and DA developed the conception and experimental design. KW, AO, and KS performed data collection, data analysis, and interpretation. KW contributed to drafting the article, critical revision of the article, final approval of the version to be published, and supervised the project.

Publisher’s note

The Publisher of the Journal remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

[1] Berre CL, Ananthakrishnan AN, Danese S, Singh S, Peyrin-Biroulet L. Ulcerative colitis and Crohn’s disease have similar burden and goals for treatment. Clin Gastroentero Hepatol 2020; 18(1):14-23.

[2] Lin Z, Luo W, Zhang K, Dai S. Environmental and microbial factors in inflammatory bowel disease model establishment: A review partly through Mendelian randomization. Gut Liver 2024; 18(3):370-390.

[3] Saez A, Herrero-Fernandez B, Gomez-Bris R, Sanchez-Martinez H, Gonzalez-Granado JM. Pathophysiology of inflammatory bowel disease: Innate immune system. Int J Mol Sci 2023; 24(2):1526.

[4] Bergemalm D, Andersson E, Hultdin J, Eriksson C, Rush ST, Kalla R, et al. Systemic inflammation in preclinical ulcerative colitis. Gastroenterology 2021; 161(5):1526-1539.e9.

[5] Malik TF, Aurelio DM. Extraintestinal manifestations of inflammatory bowel disease. In: StatPearls Internet. Treasure Island (FL): StatPearls Publishing; 2025.

[6] Angeletti A, Arrigo S, Madeo A, Molteni M, Vietti E, Arcuri L, et al. Different renal manifestations associated with very early onset pediatric inflammatory bowel disease: Case report and review of literature. BMC Nephrol 2021; 22(1):146.

[7] Dincer MT, Dincer ZT, Bakkaloglu OK, Yalin SF, Trabulus S, Celik AF, et al. Renal manifestations in inflammatory bowel disease: A cohort study during the biologic era. Med Sci Monit 2022; 28. doi: 10.12659/MSM.936497.

[8] Kumar S, Pollok R, Goldsmith D. Renal and urological disorders associated with inflammatory bowel disease. Inflamm Bowel Dis 2022; 29(8):1306-1316.

[9] Manoharan I, Swafford D, Shanmugam A, Patel N, Prasad PD, Mohamed R, et al. Genetic deletion of LRP5 and LRP 6 in macrophages exacerbates colitis-associated systemic inflammation and kidney injury in response to intestinal commensal microbiota. J Immunol 2022; 209(2):368-378.

[10] Chang CJ, Wang PC, Huang TC, Taniguchi A. Change in renal glomerular collagens and glomerular filtration barrier-related proteins in a dextran sulfate sodium-induced colitis mouse model. Int J Mol Sci 2019; 20(6):1458.

[11] Santana PT, Rosas SLB, Ribeiro BE, Marinho Y, de Souza HSP. Dysbiosis in inflammatory bowel disease: Pathogenic role and potential therapeutic targets. Int J Mol Sci 2022; 23(7):3464.

[12] Pisani A, Rausch P, Bang C, Ellul S, Tabone T, Cordina CM, et al. Dysbiosis in the gut microbiota in patients with inflammatory bowel disease during remission. Microbiol Spectr 2022; 10(3). doi: 10.1128/spectrum.00616-22.

[13] Caenepeel C, Falony G, Machiels K, Verstockt B, Goncalves PJ, Ferrante M, et al. Dysbiosis and associated stool features improve prediction of response to biological therapy in inflammatory bowel disease. Gastroenterology 2024; 166(3):483-495.

[14] Alkushi AG, Elazab ST, Abdelfattah-Hassan A, Mahfouz H, Salem GA, Sheraiba NI, et al. Multi-strain-probiotic-loaded nanoparticles reduced colon inflammation and orchestrated the expressions of tight junction, NLRP 3 inflammasome and caspase-1 genes in DSS-induced colitis model. Pharmaceutics 2022; 14(6):1183.

[15] Roselli M, Maruszak A, Grimaldi R, Harthoorn L, Finamore A. Galactooligosaccharide treatment alleviates DSS-induced colonic inflammation in Caco-2 cell model. Front Nutr 2022; 9. doi: 10.3389/fnut.2022.862974.

[16] Ma G, Chai X, Hou G, Zhao F, Meng Q. Phytochemistry, bioactivities and future prospects of mulberry leaves: A review. Food Chem 2022; 372. doi: 10.1016/j.foodchem.2021.131335.

[17] Hao J, Gao Y, Xue J, Yang Y, Yin J, Wu T, et al. Phytochemicals, pharmacological effects and molecular mechanisms of mulberry. Foods 2022; 11(8):1170.

[18] Lin Z, Gan T, Huang Y, Bao L, Liu S, Cui X, et al. Anti-inflammatory activity of mulberry leaf flavonoids in vitro and in vivo. Int J Mol Sci 2022; 23(14):7694.

[19] Wang Y, Hatabu T. Mulberry juice freeze-dried powder attenuates the disease severity by the maintaining of colon mucosa in mice with DSS-induced acute colitis. Biosci Biotechnol Biochem 2019; 83(5):914-922.

[20] Ontawong A, Wongputtisin P, Thim-Uam A, Pengnet S, Munkong N, Kuntakhut K, et al. Subchronic oral toxicity study of the synbiotic mulberry in male and female Wistar rats. Food Chem Toxicol 2024;190. doi: 10.1016/j.fct.2024.114843.

[21] Hidalgo-Cantabrana C, Algieri F, Rodriguez-Nogales A, Vezza T, Martinez-Camblor P, Margolles A, et al. Effect of a ropy exopolysaccharide-producing Bifidobacterium animalis subsp. lactis strain orally administered on DSS-induced colitis mice model. Front Microbiol 2016;7:868.

[22] Solanki MH, Chatterjee PK, Gupta M, Xue X, Plagov A, Metz MH, et al. Magnesium protects against cisplatin-induced acute kidney injury by regulating platinum accumulation. Am J Physiol Renal Physiol 2014; 307(4):F369-F384.

[23] Stangenberg S, Saad S, Schilter HC, Zaky A, Gill A, Pollock CA, et al. Lysyl oxidase-like 2 inhibition ameliorates glomerulosclerosis and albuminuria in diabetic nephropathy. Sci Rep 2018; 8(1):9423.

[24] Nguyen LT, Saad S, Shi Y, Wang R, Chou ASY, Gill A, et al. Lysyl oxidase inhibitors attenuate cyclosporin A-induced nephropathy in mouse. Sci Rep 2021; 11(1):12437. doi: 10.1038/s41598-021-91772-5.

[25] Rtibi K, Selmi S, Jabri MA, El-Benna J, Amri M, Marzouki L, et al. Protective effect of Ceratonia siliqua L. against a dextran sulfate sodium-induced alterations in liver and kidney in rat. J Med Food 2016; 19(9):882-889.

[26] Karmakova TA, Sergeeva NS, Kanukoev KY, Alekseev BY, Kaprin AD. Kidney injury molecule 1 (KIM-1): A multifunctional glycoprotein and biological marker (review). Sovrem Tekhnologii Med 2021; 13(3):64-78.

[27] Hosohata K, Ando H, Fujimura A. Early detection of renal injury using urinary vanin-1 in rats with experimental colitis. J Appl Toxicol 2014; 34(2):184-190.

[28] Hirooka Y, Nozaki Y, Niki K, Inoue A, Sugiyama M, Kinoshita K, et al. Foxp3-positive regulatory T cells contribute to antifibrotic effects in renal fibrosis via an interleukin-18 receptor signaling pathway. Front Med (Lausanne) 2020; 7. doi: 10.3389/fmed.2020.604656.

[29] Thomas JM, Ling YH, Huuskes B, Jelinic M, Sharma P, Saini N, et al. IL-18 (Interleukin-18) produced by renal tubular epithelial cells promotes renal inflammation and injury during deoxycorticosterone/salt-induced hypertension in mice. Hypertension 2021; 78(5):1296-1309.

[30] Dmochowska N, Tieu W, Keller MD, Hollis CA, Campaniello MA, Mavrangelos C, et al. ⁸⁹Zr-pro-MMP-9 F(ab’)₂ detects colitis induced intestinal and kidney fibrosis. Sci Rep 2020; 10(1):20372. doi: 10.1038/s41598-020-77390-7.

[31] Jerala M, Hauptman N, Kojc N, Zidar N. Expression of fibrosis-related genes in liver and kidney fibrosis in comparison to inflammatory bowel diseases. Cells 2022; 11(3):314.

[32] Pei Y, Zhou G, Wang P, Shi F, Ma X, Zhu J. Serum cystatin C, kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, klotho and fibroblast growth factor-23 in the early prediction of acute kidney injury associated with sepsis in a Chinese emergency cohort study. Eur J Med Res 2022; 27(1):39.

[33] Lees JS, Fabian J, Shlipak MG. Cystatin C should be routinely available for estimating kidney function. Curr Opin Nephrol Hypertens 2024; 33(3):337-343.

[34] da Paz Martins AS, de Andrade KQ, da Conceicao GCM, da Silva Gomes A, Goulart MOF, et al. Extraintestinal manifestations in induced colitis: Controversial effects of N-acetylcysteine on colon, liver, and kidney. Oxid Med Cell Longev 2023;202. doi: 10.1155/2023/8811463.

[35] Sui Y, Jiang R, Niimi M, Wang X, Xu Y, Zhang Y, et al. Gut bacteria exacerbates TNBS-induced colitis and kidney injury through oxidative stress. Redox Biol 2024; 72. doi: 10.1016/j.redox.2024.103140.

[36] Page MJ, Kell DB, Pretorius E. The role of lipopolysaccharide-induced cell signaling in chronic inflammation. Chronic Stress (Thousand Oaks) 2022;6. doi: 10.1177/24705470221076390.

[37] Refaat B, El-Boshy M. Protective antioxidative and anti-inflammatory actions of β-caryophyllene against sulfasalazine-induced nephrotoxicity in rat. Exp Biol Med (Maywood) 2022; 247(8):691-699.

[38] Mo J, Ni J, Zhang M, Xu Y, Li Y, Karim N, et al. Mulberry anthocyanins ameliorate DSS-induced ulcerative colitis by improving intestinal barrier function and modulating gut microbiota. Antioxidants (Basel) 2022; 11(9):1674.

[39] Lee D, Lee SR, Park BJ, Song JH, Kim JK, Ko Y, et al. Identification of renoprotective phytosterols from mulberry (Morus alba) fruit against cisplatin-induced cytotoxicity in LLC-PK 1 kidney cells. Plants (Basel) 2021; 10(11):2481.

[40] Tong L, Zhang X, Hao H, Liu Q, Zhou Z, Liang X, et al. Lactobacillus rhamnosus GG derived extracellular vesicles modulate gut microbiota and attenuate inflammatory in DSS-induced colitis mice. Nutrients 2021; 13(10):3319.

[41] Darwish AM, Mabrouk DM, Desouky HM, Khattab AE. Evaluation of the effectiveness of two new strains of Lactobacillus on obesity-induced kidney diseases in BALB/c mice. J Genet Eng Biotechnol 2022; 20(1):148. doi: 10.1186/s43141-022-00427-z.